Halberd Corporation (HALB)
USD 0.0
(-8.33%)
USD 0.0
(-8.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -75.05 Thousand USD | 83.22% |
| 2023 | -447.19 Thousand USD | 72.37% |
| 2022 | -1.61 Million USD | -89.16% |
| 2021 | -855.68 Thousand USD | 47.96% |
| 2020 | -1.64 Million USD | -7401.32% |
| 2019 | -21.92 Thousand USD | -54.04% |
| 2018 | -14.23 Thousand USD | 94.01% |
| 2017 | -237.56 Thousand USD | -417.81% |
| 2016 | 74.75 Thousand USD | 0.0% |
| 2008 | -37.71 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -11.11 Thousand USD | -29.21% |
| 2024 Q4 | -6885.00 USD | 38.04% |
| 2024 Q2 | -8600.00 USD | 82.1% |
| 2024 Q1 | -48.05 Thousand USD | -81.46% |
| 2023 Q3 | -80.12 Thousand USD | 25.27% |
| 2023 Q4 | -26.48 Thousand USD | 66.95% |
| 2023 Q1 | -233.38 Thousand USD | 9.78% |
| 2023 FY | -447.19 Thousand USD | 72.37% |
| 2023 Q2 | -107.21 Thousand USD | 54.06% |
| 2022 Q4 | -258.67 Thousand USD | 12.5% |
| 2022 Q3 | -295.63 Thousand USD | 58.55% |
| 2022 Q2 | -713.17 Thousand USD | -171.73% |
| 2022 FY | -1.61 Million USD | -89.16% |
| 2022 Q1 | -262.46 Thousand USD | -34.25% |
| 2021 Q4 | -195.5 Thousand USD | 14.34% |
| 2021 FY | -855.68 Thousand USD | 47.96% |
| 2021 Q3 | -228.23 Thousand USD | -23.83% |
| 2021 Q2 | -184.31 Thousand USD | 0.0% |
| 2021 Q1 | -184.31 Thousand USD | 0.0% |
| 2020 FY | -1.64 Million USD | -7401.32% |
| 2019 FY | -21.92 Thousand USD | -54.04% |
| 2018 FY | -14.23 Thousand USD | 94.01% |
| 2017 FY | -237.56 Thousand USD | -417.81% |
| 2016 FY | 74.75 Thousand USD | 0.0% |
| 2009 Q3 | -365.51 Thousand USD | -204.51% |
| 2009 Q2 | -120.03 Thousand USD | -936.64% |
| 2009 Q1 | -11.57 Thousand USD | -106.58% |
| 2008 Q3 | -156.34 Thousand USD | -172.06% |
| 2008 Q2 | -57.46 Thousand USD | -359062.5% |
| 2008 FY | -37.71 Thousand USD | 0.0% |
| 2008 Q1 | -16.00 USD | 0.0% |
| 2008 Q4 | 176.1 Thousand USD | 212.64% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 94.38% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 98.512% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.579% |
| Nascent Biotech, Inc. | -2.22 Million USD | 96.634% |
| Rebus Holdings, Inc. | -664 Thousand USD | 88.697% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.092% |
| Qrons Inc. | -643.67 Thousand USD | 88.34% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 80.735% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.865% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 81.937% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.451% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.895% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 101.527% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 71.325% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.901% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 97.367% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 95.114% |
| Mesoblast Limited | -84.14 Million USD | 99.911% |
| Marizyme, Inc. | -34.08 Million USD | 99.78% |
| Genus plc | 6.4 Million USD | 101.173% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.77% |
| Pharming Group N.V. | -4.87 Million USD | 98.462% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 96.222% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 91.942% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.101% |
| ContraFect Corporation | -56.88 Million USD | 99.868% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 98.352% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 94.647% |
| IMV Inc. | -38.67 Million USD | 99.806% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 97.272% |
| MultiCell Technologies, Inc. | -722.81 USD | -10283.088% |
| ONE Bio Corp. | 13.68 Million USD | 100.549% |
| Accustem Sciences Inc. | -3.74 Million USD | 97.997% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.873% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 84.464% |
| Q BioMed Inc. | -3.44 Million USD | 97.822% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 102.12% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 97.144% |
| Biomind Labs Inc. | -1 Million USD | 92.566% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.863% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 97.413% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 98.871% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 95.975% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -150.568% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.527% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 96.117% |
| GB Sciences, Inc. | -1.42 Million USD | 94.717% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.227% |
| HST Global, Inc. | -140.9 Thousand USD | 46.738% |
| CSL Limited | 3.7 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 93.328% |
| Enzolytics Inc. | -2.14 Million USD | 96.507% |
| Agentix Corp. | -1.37 Million USD | 94.529% |
| Resverlogix Corp. | -12.74 Million USD | 99.411% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 97.631% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.982% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 92.811% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 97.429% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 95.248% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 97.796% |
| AVAX Technologies, Inc. | 6.69 Million USD | 101.121% |
| Zenith Capital Corp. | -8.94 Million USD | 99.161% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.982% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -330.802% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 96.943% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 56.242% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 96.256% |
| Kadimastem Ltd | -3.04 Million USD | 97.531% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 92.373% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 94.025% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.035% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 58.647% |
| LadRx Corporation | -3.82 Million USD | 98.037% |
| Cell Source, Inc. | -4.32 Million USD | 98.265% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 89.075% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 89.075% |
| NovAccess Global Inc. | -2.46 Million USD | 96.958% |
| Affymax, Inc. | -15.04 Million USD | 99.501% |
| Itoco Inc. | -919.14 Thousand USD | 91.835% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 98.229% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 93.293% |
| Mobile Lads Corp. | -554.55 Thousand USD | 86.467% |
| CytoDyn Inc. | -18.05 Million USD | 99.584% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -198.172% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 65.898% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 86.71% |
| SYBLEU INC | -149.18 Thousand USD | 49.692% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 95.868% |
| International Stem Cell Corporation | -663 Thousand USD | 88.68% |
| Bioxytran, Inc. | -3.82 Million USD | 98.035% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -42.572% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -268.977% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.793% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 95.362% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 89.801% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 97.588% |
| Neutra Corp. | -229.48 Thousand USD | 67.296% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.572% |
| PureTech Health plc | -146.19 Million USD | 99.949% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.651% |
| IXICO plc | -1.43 Million USD | 94.777% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.209% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.938% |
| CSL Limited | 3.81 Billion USD | 100.002% |
| Cellectis S.A. | -108.85 Million USD | 99.931% |